Share
2,623 Posts.
lightbulb Created with Sketch. 280
clock Created with Sketch. 26/09/23
08:56
Share
Originally posted by Watmighthavben:
↑
The point is why are we even guessing what happened to patients who were dosed 3 years ago with what was initially a successful treatment program? Why is everything with Imugene left to supposition? The drug should have progressed rapidly in 2021 into an expanded phase 2 trial in partnership with a large backer who had the ability to see it through to market.IMU shareholders should be staring down the barrel of revenue from PD1 Vaxx within 2 years now, with Professor Kaumaya's other drug candidates having progressed through phase 1 trials. Lung cancer is the worlds greatest killer when it comes to cancer and Imugene's board need to be held accountable for the time it's taken to progress this outstanding and in demand drug. In flying solo it's taken Imugene far too long to develop and perform the large and extensive clinical trials required to meet FDA Approval across the broad spectrum of cancer indications available to them. Her Vaxx is a prime example. Trials are still swimming around with a handful of gastric cancer patients when a large phase 2 breast cancer trial would have catapulted the drug, given breast cancer is the leading Her 2 indication. Imugene's tardiness in taking a large partner on board has meant others such as Enhertu have crept into what is now a competitive space.
Expand
So, the bigger questions to ask is, why go it alone. Was a deal rejected, is it just ego or would a deal have ruined plans to drag this out and suck holders dry.
(20min delay)